CA-TTTECH-INDUSTRIAL
TTTech Industrial Automation AG has acquired core technology and strategic customers from pioneering fog/edge computing start-up Nebbiolo Technologies in a deal closed in May. Integrating features and know-how from Nebbiolo Technologies will support TTTech Industrial’s commitment to delivering the world’s most advanced industrial edge computing platform to its customers. TTTech Industrial has also founded a US subsidiary in Silicon Valley to expand its activities in the North American market. Kannan Devarajan, one of the co-founders of Nebbiolo Technologies has joined TTTech Industrial North America Inc. as Managing Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005037/en/
TTTech Industrial is a leading provider of industrial IoT solutions, and partners with key players in IoT such as Intel and Microsoft. The company’s Nerve software platform has been at the forefront of industrial edge computing since its launch in 2016. The foundation of TTTech Industrial North America supports the expansion of commercial operations in the US and Canada, with the technology and customer assets acquired from Nebbiolo Technologies forming the nucleus of these activities.
Nebbiolo Technologies is renowned as the pioneer of fog computing, with patented technology that is foundational to industrial edge computing concepts. The company was named a Gartner Cool Vendor in 2017 and was recognized as the Customer Value Leader in the IIoT edge computing market by Frost & Sullivan in 2019. The combination of existing Nerve product features with Nebbiolo Technologies’ expertise will provide customers with an unparalleled solution for software management at the edge, remote connectivity, edge analytics, high-availability, and security.
TTTech Industrial has an existing customer base of machine builders and system integrators based in Europe, the US and Asia. Aside from growing its operations in North America and Asia, this deal also allows TTTech Industrial to widen the scope of its activities to new industries such as energy, oil/gas and auto manufacturing, strengthen the global reach of its edge computing solutions and bolster go-to-market activities in Europe.
"The launch of our US subsidiary marks a significant step for our company. Our location in Silicon Valley brings us closer to customers and allows us to tap into a pool of the world's best software engineering talent. The integration of assets from Nebbiolo Technologies enables us to offer even more advanced industrial edge computing solutions to new and existing customers in a wider range of application fields,” explains Thomas Berndorfer, Member of the Executive Board, TTTech Industrial Automation AG.
“I am very proud to be leading TTTech Industrial's expansion into North America. My team and I bring a wealth of experience in edge computing solutions that will contribute to making Nerve the platform of choice for industrial automation customers. In addition, we will provide customers with expert local sales and technical support, as well as custom feature development," says Kannan Devarajan, Managing Director, TTTech Industrial North America.
CEO and co-founder of Nebbiolo Technologies Chandra Joshi states, “We have been partnering with TTTech Industrial from the outset of our journey. I am confident that the integration of Nebbiolo’s technology with TTTech Industrial’s Nerve product line will create a leading-edge computing platform to enable existing and new customers to accelerate their digital transformation.”
About TTTech Industrial Automation AG
TTTech Industrial aspires to unlock the incredible potential of industrial automation. It combines transformative technologies with hands-on experience in critical real-time systems to offer customers flexibility, reliability and choice. TTTech Industrial operates under the umbrella of the TTTech Group, a leading provider of safe networked computing platforms, with cross-industry experience from more than 20 years of operation.
TTTech Industrial product lines Nerve, Slate and Flexibilis are designed to converge and connect automation systems. Nerve is a flexible, open industrial edge computing platform that enables users to access data, manage devices and deploy applications remotely. Slate is a deterministic networking platform that provides comprehensive TSN solutions. Flexibilis is a redundant networking product portfolio that delivers high-availability seamless redundancy for a wide range of industrial applications, most notably in the energy industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom